These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 24619745)

  • 1. Triple-negative breast carcinoma: current and emerging concepts.
    Schmadeka R; Harmon BE; Singh M
    Am J Clin Pathol; 2014 Apr; 141(4):462-77. PubMed ID: 24619745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-cadherin and vimentin are useful basal markers in breast cancers.
    Tsang JY; Au SK; Ni YB; Shao MM; Siu WM; Hui SW; Chan SK; Chan KW; Kwok YK; Chan KF; Tse GM
    Hum Pathol; 2013 Dec; 44(12):2782-91. PubMed ID: 24139214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
    Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
    Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
    Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
    Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of the X-linked inhibitor of apoptosis protein for invasive ductal breast cancer with triple-negative phenotype.
    Wang J; Liu Y; Ji R; Gu Q; Zhao X; Liu Y; Sun B
    Hum Pathol; 2010 Aug; 41(8):1186-95. PubMed ID: 20381828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
    Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
    Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-negative Breast Carcinoma: Morphologic and Molecular Subtypes.
    Bose S
    Adv Anat Pathol; 2015 Sep; 22(5):306-13. PubMed ID: 26262513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 55-Year-Old Woman With New Triple-Negative Breast Mass, Less Than 2 cm on Both Mammogram and Ultrasound.
    Elias AD; Wang WS; Hardesty L
    Oncology (Williston Park); 2016 Mar; 30(3):258-62. PubMed ID: 26984221
    [No Abstract]   [Full Text] [Related]  

  • 10. The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast.
    Choi Y; Kim EJ; Seol H; Lee HE; Jang MJ; Kim SM; Kim JH; Kim SW; Choe G; Park SY
    Hum Pathol; 2012 Jan; 43(1):48-55. PubMed ID: 21733550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
    Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
    Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TTF-1 positive breast cancer: a cautionary tale.
    Ellery P; Archard N; Saetta A; Gandy M; Falzon M
    J Clin Pathol; 2015 Aug; 68(8):665-6. PubMed ID: 25918229
    [No Abstract]   [Full Text] [Related]  

  • 13. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
    Tas F
    Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
    Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
    Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical impact of new treatments in breast cancer.
    Alkatout I; Order B; Klapper W; Weigel MT; Jonat W; Schaefer FK; Mundhenke C; Wenners A
    Minerva Ginecol; 2013 Aug; 65(4):363-83. PubMed ID: 24051938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer.
    Koo JS; Jung W
    Pathobiology; 2010; 77(6):289-300. PubMed ID: 21266827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
    Rydén L; Jirström K; Haglund M; Stål O; Fernö M
    Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
    Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
    Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNAs as regulatory elements in triple negative breast cancer.
    Gyparaki MT; Basdra EK; Papavassiliou AG
    Cancer Lett; 2014 Nov; 354(1):1-4. PubMed ID: 25107641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer.
    Li J; Liu X; Tong Z
    Jpn J Clin Oncol; 2012 Jun; 42(6):471-6. PubMed ID: 22493058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.